Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease

[Image: see text] The molecular origin of sickle cell disease (SCD) has been known since 1949, but treatments remain limited. We present the first high-throughput screening (HTS) platform for discovering small molecules that directly inhibit sickle hemoglobin (HbS) oligomerization and improve blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Vunnam, Nagamani, Hansen, Scott, Williams, Dillon C., Been, MaryJane Olivia, Lo, Chih Hung, Pandey, Anil K., Paulson, Carolyn N., Rohde, John A., Thomas, David D., Sachs, Jonathan N., Wood, David K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472799/
https://www.ncbi.nlm.nih.gov/pubmed/35944154
http://dx.doi.org/10.1021/acs.biomac.2c00671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472799/
https://www.ncbi.nlm.nih.gov/pubmed/35944154
http://dx.doi.org/10.1021/acs.biomac.2c00671

Ejemplares similares